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9 ABSTRACT: The ﬁrst asymmetric, Brønsted acid catalyzed Biginelli-like reaction of a ketone has been developed, employing N-
10 substituted isatins as carbonyl substrates, and urea and alkyl acetoacetates as further components. BINOL-derived phosphoric
11 acid catalysts have been used to achieve the synthesis of a small library of chiral, enantioenriched spiro(indoline-pyrimidine)-
12 diones derivatives. The absolute conﬁguration of the new spiro stereocenter was assessed on diastereoisomeric derivatives
13 through computer-assisted NMR spectroscopy. X-ray diﬀractometry allowed the disclosure of the overall molecular conformation
14 in the solid state and the characterization of the crystal packing of a Br-substituted Biginelli-like derivative, while computational
15 studies on the reaction transition state allowed us to rationalize the stereochemical outcome.
16 ■ INTRODUCTION
17 2-Oxindoles, especially those 3,3-disubstituted or spiro-fused to
18 other cyclic frameworks, continue to be recognized as valuable
19 compounds for drug discovery. They feature in a large number
20 of natural and unnatural compounds with important biological
21 activities and serve as key intermediates for the synthesis of
22 many kinds of drug candidates.1
23 In particular, spirooxindoles, having cyclic structures fused at
24 the C3 carbon, move away from the ﬂat heterocycles
25 encountered in many drug discovery programs. For this reason,
26 they are of special interest, being able to potentially provide
27 improved physicochemical properties in their interaction with
28 biological systems.2
29 As more examples of the enantiospeciﬁc biological activity
30 are identiﬁed, eﬃcient and reliable asymmetric synthesis of
31 such compounds becomes ever more valuable. In particular, the
32 improvement of practical and versatile multicomponent
33 approaches has attracted considerable interest owing to their
34 synthetic eﬃciency and extensive diversity-generating ability.3
35 Multicomponent reactions (MCRs) are very eﬃcient tools to
36 quickly prepare pharmacological compounds. However, their
37 combination with asymmetric catalysis, in particular organo-
38 catalysis, remains a largely unmined area of research, although
39 the results reported until now show the possibilities and
40versatility of this type of strategy, which allows elevated levels of
41atom eﬃciency and enantioselectivity to be reached at the same
42time.4 In the ﬁeld of oxindole chemistry, to date, only a few
43organocatalyzed multicomponent methods have been reported
44toward the asymmetric generation of the structurally rigid
45architecture of 3,3-disubstituted or spiro-fused oxindoles.5
46Noteworthy among them is the cinchona alkaloid derived
47amine-catalyzed Michael-type addition developed in highly
48eﬃcient three-component versions using readily available
49malononitrile, isatins, and ketones.6,7 Quite recently, isatin-
50derived 3-indolylmethanols have emerged as useful substrates
51for phosphoric acid catalyzed three-component cascade
52Michael/Pictet-Spengler reactions.8 On the other hand, intense
53eﬀort have been devoted to develop organocatalytic MCRs to
54form spiro[pyrrolidin-3,2′-oxindoles] and spirooxindole pyran
55derivatives by means of 1,3-dipolar cycloadditions9 or cascade
56[3 + 2]10 or [2 + 2 + 2] cycloadditions.11
57As part of our interest in the asymmetric synthesis of 3,3-
58disubstituted oxindole derivatives and related spiro-com-
59pounds,12 we turned our attention to the MCRs ﬁeld, in
60order to explore the single reactant replacement (SRR)
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61 approach.13 By this strategy, starting from a well-known MCR,
62 new applications can be found; just replacing a single
63 component with a diﬀerent input enabled to carry out the
64 key chemical reactivity necessary for that MCR to occur. In this
65 context, we focused on the Biginelli reaction, one of the well-
66 established MCRs, mainly employed for the synthesis of 3,4-
67 dihydropyrimidine-2(1H)-ones (DHPMs). Such heterocyclic
68 scaﬀolds have found increasing applications in medicinal
69 chemistry, because of their important pharmacological and
70 biological properties.14 Only few examples are reported on
71 enantioselective organocatalytic Biginelli reactions, all involving
72 aromatic aldehydes as carbonyl components.15 The milestone
73 was placed by Gong,16−18 who disclosed the ﬁrst highly
74 enantioselective protocol, based on BINOL-derived chiral
75 phosphoric acids as organocatalysts. Also, dual-activation routes
76 have been developed, by using combined catalysts consisting of
77a Brønsted acid and a chiral secondary amine19,20 or,
78alternatively, a chiral bifunctional primary amine-thiourea.21
79To the best of our knowledge, only two examples of the
80multicomponent preparation of racemic DHPMs derivatives
81starting from isatin are reported.22,23 In general, application of
82organocatalysis to the Biginelli-like reaction, employing a
83ketone as the carbonyl component, is even now quite
84unexplored. Herein, we report the Brønsted acid catalyzed
85asymmetric synthesis of spiro(indoline-pyrimidine)-diones
86derivatives via a Biginelli-like reaction, consisting of a three-
87component cyclocondensation of alkyl acetoacetates, urea, and
88 s1isatin derivatives instead of aldehydes (Scheme 1).
89■ RESULTS AND DISCUSSION
90Our initial studies were performed taking into account the
91Brønsted acid catalytic enantioselective protocol reported by
Scheme 1. Strategy Used for the Asymmetric Construction of the Spiro(indoline-pyrimidine)-dione Scaﬀold
Table 1. Optimization of the Asymmetric Biginelli-like Reactiona
entry catalyst solvent conc. [mol/L] temp. [°C], time [h] yieldb [%] eec [%]
1 4a CH2Cl2 0.2 rt, 96 trace
2 4a toluene 0.2 rt, 96 trace
3 4a CH2Cl2 0.2 50, 48 32 75
4 4a toluene 0.2 50, 48 51 80
5 4b toluene 0.2 50, 48 trace
6 4c toluene 0.2 50, 48 30 79
7 4d toluene 0.2 50, 48 31 81
8 4e toluene 0.2 50, 48 trace
9 4f toluene 0.2 50, 48 trace
10 4g toluene 0.2 50, 48 26 79
11 4a toluene 0.2 50, 96 60 80
12 4a toluene 0.2 50, 240 66 77
13 4a toluene 0.2 70, 96 65 48
14 4a toluene 0.4 50, 96 62 66
aReactions were performed on a 0.16 mmol scale with 1/2/3 in a 1/1.2/3 ratio, in the presence of 20 mol % (R)-4 (0.032 mmol). bIsolated yield.
cDetermined by chiral HPLC analysis.
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92 Gong for the true, aldehyde-involving, Biginelli reaction. Isatin
93 1a, urea 2, ethyl acetoacetate 3, and (R)-BINOL-derived
94 phosphoric acid 4a were chosen for preliminary experiments
t1 95 (Table 1).
96 At room temperature, the reaction proceeds with diﬃculty
97 both in CH2Cl2 and in toluene (entries 1 and 2), and after 96 h,
98 only trace amounts of the desired compound 5a could be
99 detected by 1H NMR of the crude reaction mixture. The lower
100 reactivity of the C-3 carbonyl group of isatin compared to
101 aldehydes, along with its higher steric demand, appears to be
102 the key factor hindering the reaction from successfully
103 proceeding at room temperature.
104 To our delight, increasing the temperature to 50 °C (entries
105 3 and 4) entailed a signiﬁcant eﬀect on the chemical
106 conversion. Toluene proved to be the solvent of choice,
107 aﬀording product 5a in acceptable yield and with a good level
108 of enantioselectivity. Screening of more hindered catalysts 4b−
109 f, aimed to evaluate the impact of the 3,3′-substitution, and of
110 octahydro-BINOL-based 4g, was performed (entries 5−10).
111 Increasing the size of the 3,3′-substituents on the phosphoric
112 acid proved detrimental for the chemical conversion, with only
113 catalysts 4c and 4d able to aﬀord product 5a, with maintenance
114 of the same level of enantioselectivity as 4a, but in deﬁnitely
115 decreased yields. After that, we established 4a as the catalyst of
116 choice, and further screening of the reaction conditions was
117 performed. Some yield improvement without sacriﬁcing the
118 stereoselectivity could be achieved by prolonging the reaction
119 time until 96 h (entry 11). More prolonged times are not
120 convenient for the balance among yield and ee (entry 12).
121Increasing the reaction temperature deeply eroded the
122enantioselectivity, albeit with better yield (entry 13). The
123same happened when the reaction was conducted in more
124concentrated conditions (entry 14). Lowering the reactant
125concentration or the catalyst loading led to a signiﬁcant
126decrease in yield.
127After establishing the optimal conditions, the Biginelli-like
128reaction of a isatins series was examined, using (R)-4a as
129 f1catalyst, in toluene at 50 °C for 96 h (Figure 1).
130The substrate scope was surveyed, by evaluating diﬀerently
131N-substituted isatins and the presence of substituents at the 5-
132or 6-position of the isatin nucleus. In general, all isatins readily
133undergo this reaction, to aﬀord the desired products 5a−h in
134moderate to high yields, with a good degree of enantiose-
135lectivity. Only the sterically demanding N-trityl isatin failed to
136participate in the reaction, and the corresponding Biginelli-like
137adduct could not be detected. The N-Me isatin gave a better
138result than the corresponding N-benzyl, N-p-nitrobenzyl, and
139N-p-methoxybenzyl ones in terms of yield (93% in comparison
140to up to 63%), but suﬀering a drop in ee (50% in comparison to
141up to 80%).
142The presence of various halogen substituents at the aryl ring
143has almost no eﬀect on both yield and ee. Variations at the ester
144moiety of the β-ketoester component were also evaluated.
145Methyl and benzyl acetoacetates participated at the reaction
146eﬃciently to provide adducts 5i−j in good yields and moderate
147ee’s.
148In this kind of reaction, surprisingly, neither thiourea in place
149of urea nor various linear or cyclic β-diketones in place of alkyl
Figure 1. Substrate scope of the Biginelli-like reaction catalyzed by (R)-4a.
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150 acetoacetates showed to be suitable, together with N-benzyl-
151 isatin. With thiourea, no reaction occurred, whereas, with β-
152 diketones, a complex mixture of products could be detected.
153 Then, we examined some product transformations, ﬁrst of all,
154 the facile regioselective mono-N-alkylation of the dihydropyr-
155 imidin-2-one ring. Starting from the Biginelli-like compound
156 5a, the corresponding N-benzyl derivative 6 was achieved in
157 high yield and regioselectivity, by reaction with benzyl bromide
s2 158 and cesium carbonate, in DMF at room temperature (Scheme
s2 159 2).
160 Further, catalytic hydrogenolysis of the benzyl ester moiety
161 of compound 5j allowed us to easily obtain the carboxylic acid
162 derivative 7, which can be regarded as a useful key intermediate
163 toward the synthesis of peptidomimetic compounds. The
164 carboxylic acid functional group of 7 can also be quantitatively
165 removed to give 8, by heating in acidic conditions.
166 In order to demonstrate the reactivity of acid 7 and aiming at
167 the same time to gain information on the absolute
168 conﬁguration of the major enantiomer 5j (vide inf ra), obtained
169 in the (R)-4a-catalyzed Biginelli-like reaction, we pursued the
s3 170 transformation depicted in Scheme 3.
171 By reaction with (S)-1-phenylethanamine in the presence of
172 the condensing agent HATU, acid 7 was cleanly converted into
173 diastereoisomeric amides 9a and 9b, which could be eﬃciently
174 separated by ﬂash chromatography, establishing the possible
175 application of 7 in peptidomimetic chemistry.
176 Conﬁding at ﬁrst on X-ray diﬀractometry in order to
177 determine the C3 absolute conﬁguration of compounds 5, we
178 planned to perform the crystallographic analysis on 5h. This
179 molecule was selected as a suitable derivative, due to the
180 presence of the bromine atom as anomalous dispersor. Initially,
181 5h disclosed a recalcitrant crystallization behavior in yielding
182single crystals and, only after many attempts, well diﬀracting
183crystals were obtained. The X-ray data revealed that the 12:88
184molar mixture of enantiomers crystallized in a centrosymmetric
185space group, showing the more favored crystallization of the
186racemate instead of the major enantiomer. In the solid state, the
187overall molecular conformation is determined by the spiro-
188(indoline-pyrimidine)-dione system, with the dihydropyrimi-
189din-2-one ring, having an almost planar conformation,
190 f2perpendicularly oriented with respect to oxindole (Figure 2a).
191The conformation of the benzyl group shows the phenyl ring
192pointing in the same direction of the dihydropyrimidin-2-one
193carbonyl moiety (see the Supporting Information). The crystal
194packing is characterized by strong centrosymmetric N−H···O
Scheme 2. Synthetic Transformations of Compounds 5a and 5j
Scheme 3. Synthesis of Diastereoisomeric Compounds 9a and 9b, Starting from Acid 7
Figure 2. (a) ORTEP25 drawing of 5h, showing the arbitrary atomic
numbering (displacement ellipsoids at 40% probability). (b)
Intermolecular interactions viewed along the c axis.
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195 hydrogen bonds, leading to the formation of dimers, that are in
196 turn stabilized by Cπ−H···O contacts, as depicted in Figure 2b.
197 This interaction pattern can be employed for rationalizing the
198 preferential crystallization of the racemate, which is indeed
199 consistent with the close packing found in the crystal
200 environment, dominated by unique characteristics of hydrogen
201 bonds involved in dimer formation. This easier racemate
202 crystallization is in agreement with previous literature data,24
203 showing the tendency for several racemic crystals to be more
204 stable and denser than their chiral counterparts.
205 Although it was not possible to obtain suitable crystals for X-
206 ray-based determination of the prevailing enantiomer 5h, we
207 were able to determine the C3 stereochemistry through ab
208 initio calculation of NMR shifts, a technique pioneered by
209 Bifulco.26 We considered the diﬀerences in both 1H and 13C
210 NMR spectra for compounds 9a and 9b and then performed a
211 theoretical conformational search on both (3S,1′S) and
212 (3R,1′S) possible diastereoisomers, employing the Monte
213 Carlo algorithm and molecular mechanics (MMFF force
214 ﬁeld). After DFT optimization, we calculated 1H and 13C
215 NMR chemical shifts, by subjecting the shielding constants to
216 Boltzmann averaging over the conformers, followed by linear
217 regression, as reported by Pierens.27 From comparison of
218 experimental and calculated data, the (3S,1′S) absolute
219 conﬁguration could be conﬁdently assigned to the major
220 diastereoisomer 9a and, consequently, the (3R,1′S) one to the
221 minor 9b. To make this assignment safe beyond any doubt, we
222 also calculated the comparison parameter (CP3), especially
223 designed28 for the computer-assisted assignment of the
224 stereochemistry of diastereoisomer pairs, in which only the
225 conﬁguration of one stereocenter is unknown. By this way, our
226 stereochemical assignment could be made quite secure also
227 from a quantitative point of view (see the Supporting
228 Information).
229 These results allowed us to disclose the C3-S favoring
230 enantioselectivity of the described organocatalyzed reaction and
231 prompted us to perform theoretical calculations on the
232 stereogenic center forming step. The mechanism of the
233 Biginelli reaction has been previously investigated by means
234 of computational tools,29 also in the presence of tartaric acid as
235 catalyst.30 Results indicated the iminium path as the most
236 favorable, in accordance with a previously proposed mecha-
237 nism.31 Therefore, we decided to investigate the initial addition
238of the enol form of ethyl acetoacetate on the imine formed
239between isatin 1a and urea 2, in the presence of (R)-4a, since,
240in this step, the ﬁnal conﬁguration of 5a is determined. DFT
241study at the B3LYP/6-31G(d,p) level of theory was performed
242taking into account the two possible spatial arrangements of the
243more stable Z-imine in the reagents−catalyst complex,32
244leading to the diastereoisomeric transition state models TS-A
245 f3and TS-B (Figure 3). All the calculations were performed with
246the Spartan ’0833 suite (see the Supporting Information). The
247energy proﬁles clearly indicate a strong preference for TS-A,
248with a ΔΔG⧧ = 1.47 kcal/mol with respect to TS-B, at T = 323
249K, from which an expected 85% ee could be calculated. These
250results are in satisfactory agreement with the experimental
251observed ee’s, and once again support the previously predicted S
252conﬁguration for major diastereoisomer 9a.
253Looking at the transition state 3D structures, the steric
254hindrance between one phenyl substituent of (R)-4a and the
255ureidic residue could explain the higher activation energy of
256TS-B and the resulting favored nucleophilic attack on the si-face
257of the imine (TS-A). Moreover, in TS-A, a hydrogen bond
258between the ureidic NH of the imine and the carbonyl oxygen
259of the acetoacetate ester is established, thus further stabilizing
260this structure.
261■ CONCLUSION
262In conclusion, we developed the ﬁrst enantioselective organo-
263catalyzed Biginelli-like reaction applied to a ketone, namely,
264isatin, with good yields and enantioselectivity. By employing
265BINOL-based phosphoric acids as catalysts and diﬀerent isatins
266and alkyl acetoacetates as substrates, together with urea, a small
267library of enantioenriched spiro[indoline-pyrimidine]-dione
268derivatives could be obtained. Postcondensation reactions
269have been performed, increasing the number of potentially
270useful compounds.
271The solid state conformation of a Br-containing Biginelli-like
272compound was investigated, putting in evidence its crystal-
273lization behavior leading to the more favored racemate, instead
274of the major enantiomer. The absolute conﬁguration at the
275oxindole C3 quaternary stereocenter was assessed to be S for
276the major enantiomer, by means of quantum mechanical
277methods and NMR spectroscopy on diastereoisomeric
278derivatives. Computational studies on the reaction transition
Figure 3. Proposed transition states TS-A and TS-B (and the corresponding 3D structures) of the BINOL-derived phosphoric acid catalyzed
Biginelli-like reaction to give 5a. In 3D, TS-B red lines highlight the steric hindrance between one phenyl substituent of (R)-4a and the ureidic
residue.
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279 state (TS) allowed us to explain the experimentally observed
280 enantioselectivity and stereochemical outcome.
281 ■ EXPERIMENTAL SECTION
282 General Information. All commercial materials were used without
283 further puriﬁcation. All solvents were of reagent grade or HPLC grade.
284 All reactions were carried out under a nitrogen atmosphere unless
285 otherwise noted. All reactions were monitored by thin-layer
286 chromatography (TLC) on precoated silica gel 60 F254; spots were
287 visualized with UV light or by treatment with a 1% aqueous KMnO4
288 solution. Products were puriﬁed by ﬂash chromatography on silica gel
289 60 (230−400 mesh). 1H NMR spectra and 13C NMR spectra were
290 recorded on 300 and 400 MHz spectrometers. Chemical shifts are
291 reported in parts per million relative to the residual solvent. 13C NMR
292 spectra have been recorded using the APT pulse sequence.
293 Multiplicities in 1H NMR are reported as follows: s = singlet, d =
294 doublet, t = triplet, m = multiplet, br s = broad singlet. High-resolution
295 MS spectra were recorded with a Q-TOF mass spectrometer, equipped
296 with an ESI source. Chiral HPLC analysis was performed with a UV
297 detector and binary HPLC pump at 254 nm. A Chiralcel OD column
298 was used. Speciﬁc optical rotation [α]D
T was measured with a cell of 1
299 dm path length and 1 mL capacity. The light used has a wavelength of
300 589 nm (sodium D line). N-Substituted isatins34 and BINOL-
301 phosphoric acids35 were synthesized according to the reported
302 literature.
303 General Procedure for the Asymmetric Organocatalyzed
304 Synthesis of Compounds 5a−j. Substituted isatin 1 (0.16 mmol, 1
305 equiv), urea 2 (0.19 mmol, 1.2 equiv), alkyl acetoacetate 3 (0.48
306 mmol, 3 equiv), and (R)-4a catalyst (0.03 mmol, 0.2 equiv) were
307 dissolved in toluene (0.800 mL, 0.2 M). The reaction was stirred at 50
308 °C for 96 h. The resulting mixture was then concentrated under
309 reduced pressure, to give a residue which was puriﬁed by ﬂash
310 chromatography (FC) as indicated below.
311 (S)-Ethyl 1-Benzyl-6′-methyl-2,2′-dioxo-2′,3′-dihydro-1′H-spiro-
312 [indoline-3,4′-pyrimidine]-5′-carboxylate 5a. Prepared according to
313 the general procedure starting from N-benzyl isatin and ethyl
314 acetoacetate; FC:dichloromethane:methanol, 97.5:2.5; yield: 60%;
315 white solid; mp 223−224 °C; [α]D20 − 45.5 (c 0.2, CHCl3); 1H
316 NMR (400 MHz, CDCl3) δ 8.50 (br s, 1H), 7.42 (d, J = 7.4 Hz, 2H),
317 7.38−7.24 (m, 4H), 7.21 (t, J = 7.5 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H),
318 6.76 (d, J = 7.8 Hz, 1H), 5.69 (br s, 1H), 4.99 (d, J = 15.5 Hz, 1H),
319 4.80 (d, J = 15.5 Hz, 1H), 3.99−3.86 (m, 1H), 3.70−3.55 (m, 1H),
320 2.38 (s, 3H), 0.71 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ
321 176.5, 165.2, 151.9, 149.9, 143.2, 136.3, 132.9, 130.5, 129.5 (2C),
322 128.5 (3C), 124.6, 124.0, 109.9, 99.4, 64.2, 60.6, 45.0, 20.1, 14.1;
323 HRMS (ESI) calcd for C22H21N3NaO4
+ [MNa]+ 414.1434, found
324 414.1442; enantiomeric excess: 80%, determined by chiral HPLC (n-
325 hexane:isopropanol = 80:20, ﬂow rate 1.0 mL/min): tR = 14.98 min
326 (major), tR = 33.78 min (minor).
327 (S)-Ethyl 1-(4-Methoxybenzyl)-6′-methyl-2,2′-dioxo-2′,3′-dihy-
328 dro-1′H-spiro[indoline-3,4′-pyrimidine]-5′-carboxylate 5b. Prepared
329 according to the general procedure starting from N-(4-methoxybenzyl)
330 isatin and ethyl acetoacetate; FC:dichloromethane:methanol, 97.5:2.5;
331 yield: 63%; white solid; mp 193−194 °C; [α]D20 + 4.5 (c 0.35, CHCl3);
332
1H NMR (300 MHz, CDCl3, mixture of conformers 6:1) δ 8.87 (br s,
333 0.15H), 8.74 (br s, 0.85H), 7.33 (d, J = 8.7 Hz, 2H), 7.26 (d, J = 8.2
334 Hz, 1H), 7.17 (t, J = 7.7 Hz, 1H), 6.98 (t, J = 7.3 Hz, 1H), 6.88−6.70
335 (m, 3H), 6.01 (br s, 0.86H), 5.81 (br s, 0.14H), 4.85 (d, J = 15.3 Hz,
336 1H), 4.71 (d, J = 15.3 Hz, 1H), 3.96−3.78 (m, 1H), 3.74 (s, 0.43H),
337 3.71 (s, 2.57H), 3.64−3.43 (m, 1H), 2.33 (s, 0.44H), 2.27 (s, 2.56H),
338 0.64 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3, mixture of
339 conformers 6:1) δ 175.9, 164.6, 159.1, 152.1, 149.5, 142.6, 132.5,
340 129.7, 129.2 (2C), 127.8, 123.9, 123.2, 114.1 (2C), 109.2, 98.5, 63.4,
341 59.8, 55.2, 43.7, 19.1, 13.5; HRMS (ESI) calcd for C23H23N3NaO5
+
342 [MNa]+ 444.1530, found 444.1519; enantiomeric excess: 75%,
343 determined by chiral HPLC (n-hexane:isopropanol = 65:35, ﬂow
344 rate 1.0 mL/min): tR = 9.85 min (major), tR = 27.96 min (minor).
345 (S)-Ethyl 6′-Methyl-1-(4-nitrobenzyl)-2,2′-dioxo-2′,3′-dihydro-
346 1′H-spiro[indoline-3,4′-pyrimidine]-5′-carboxylate 5c. Prepared ac-
347 cording to the general procedure starting from N-(4-nitrobenzyl)
348isatin and ethyl acetoacetate; FC:dichloromethane:methanol, 97.5:2.5;
349yield: 49%; white solid; mp 201−202 °C; [α]D20 − 8.2 (c 0.3, CHCl3);
350
1H NMR (300 MHz, CDCl3, mixture of conformers 5:1) δ 8.48 (br s,
3510.17H), 8.40 (br s, 0.83H), 8.21−8.08 (m, 2H), 7.65−7.54 (m, 2H),
3527.30 (d, J = 7.3 Hz, 1H), 7.19 (t, J = 7.3 Hz, 1H), 7.03 (t, J = 7.5 Hz,
3531H), 6.62 (d, J = 7.6 Hz, 1H), 6.28 (br s, 0.84H), 6.12 (br s, 0.16H),
3545.09−4.87 (m, 2H), 4.07−3.89 (m, 1H), 3.86−3.68 (m, 1H), 2.34 (s,
3550.5H), 2.30 (s, 2.5H), 0.88 (m, 3H). 13C NMR (75 MHz, CDCl3,
356mixture of conformers 5:1) δ 176.0, 164.6, 151.8, 149.0, 147.5, 143.0,
357141.9, 132.2, 130.0, 128.4 (2C), 124.1, 124.0 (2C), 123.8, 109.0, 98.9,
35863.51, 60.3, 43.7, 19.5, 13.8; HRMS (ESI) calcd for C22H20N4NaO6
+
359[MNa]+ 459.1275, found 459.1268; enantiomeric excess: 70%,
360determined by chiral HPLC (n-hexane:isopropanol = 50:50, ﬂow
361rate 1.0 mL/min): tR = 10.05 min (major), tR = 45.50 min (minor).
362(S)-Ethyl 1,6′-Dimethyl-2,2′-dioxo-2′,3′-dihydro-1′H-spiro-
363[indoline-3,4′-pyrimidine]-5′-carboxylate 5d. Prepared according to
364the general procedure starting from N-methyl isatin and ethyl
365acetoacetate; FC:dichloromethane:methanol, 95:5; yield: 93%; white
366solid; mp 228−229 °C; [α]D20 − 1.6 (c 0.35, CHCl3); 1H NMR (400
367MHz, DMSO-d6) δ 9.45 (br s, 1H), 7.75 (br s, 1H), 7.30 (t, J = 7.7 Hz,
3681H), 7.18 (d, J = 7.3 Hz, 1H), 7.01 (t, J = 7.4 Hz, 1H), 6.97 (d, J = 7.8
369Hz, 1H), 3.68 (q, J = 7.1 Hz, 2H), 3.10 (s, 3H), 2.26 (s, 3H), 0.75 (t, J
370= 7.1 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ 176.2, 164.8, 150.9
371(2C), 144.0, 134.0, 129.6, 123.4, 122.8, 108.7, 97.1, 63.1, 59.5, 26.6,
37218.7, 13.8; HRMS (ESI) calcd for C16H17N3NaO4
+ [MNa]+ 338.1111,
373found 338.1123; enantiomeric excess: 50%, determined by chiral
374HPLC (n-hexane:isopropanol = 65:35, ﬂow rate 1.0 mL/min): tR =
3757.25 min (major), tR = 38.20 min (minor).
376(S)-Ethyl 1-Benzyl-5-ﬂuoro-6′-methyl-2,2′-dioxo-2′,3′-dihydro-
3771′H-spiro[indoline-3,4′-pyrimidine]-5′-carboxylate 5e. Prepared ac-
378cording to the general procedure starting from 5-ﬂuoro-N-benzyl isatin
379and ethyl acetoacetate; FC:dichloromethane:methanol, 97.5:2.5; yield:
38051%; white solid; mp 135−136 °C; [α]D20 + 3.8 (c 0.3, CHCl3); 1H
381NMR (300 MHz, CDCl3, mixture of conformers 5:1) δ 8.76−8.49 (br,
382m, 1H), 7.38 (d, J = 7.2 Hz, 2H), 7.34−7.16 (m, 3H), 7.03 (dd, J = 7.3,
3832.5 Hz, 1H), 6.88 (td, J = 8.8, 2.4 Hz, 1H), 6.67 (dd, J = 8.5, 3.8 Hz,
3841H), 6.13−5.88 (br, m, 1H), 4.92 (d, J = 15.5 Hz, 1H), 4.76 (d, J =
38515.5 Hz, 1H), 4.04−3.83 (m, 1H), 3.74−3.52 (m, 1H), 2.35 (s, 0.5H),
3862.30 (s, 2.5H), 0.83−0.68 (m, 3H). 13C NMR (75 MHz, CDCl3,
387mixture of conformers 5:1) δ 175.7, 164.4, 161.1, 157.9, 151.80,
388149.75, 138.42, 135.34, 128.77 (2C), 127.81, 127.74 (2C), 116.17 and
389115.86 (1C), 112.19 and 111.9 (1C), 110.0 and 109.9 (1C), 98.2, 63.6,
39060.1, 44.4, 19.3, 13.6; HRMS (ESI) calcd for C22H20FN3NaO4
+
391[MNa]+ 432.1330, found 432.1326; enantiomeric excess: 75%,
392determined by chiral HPLC (n-hexane:isopropanol = 70:30, ﬂow
393rate 1.0 mL/min): tR = 8.15 min (major), tR = 16.35 min (minor).
394(S)-Ethyl 1-Benzyl-5-chloro-6′-methyl-2,2′-dioxo-2′,3′-dihydro-
3951′H-spiro[indoline-3,4′-pyrimidine]-5′-carboxylate 5f. Prepared ac-
396cording to the general procedure starting from 5-chloro-N-benzyl
397isatin and ethyl acetoacetate; FC:dichloromethane:methanol, 97.5:2.5;
398yield: 66%; white solid; mp 126−127 °C; [α]D20 + 33.6 (c 0.2, CHCl3);
399
1H NMR (300 MHz, CDCl3, mixture of conformers 5:1) δ 8.76 (br s,
4000.16H), 8.69 (br s, 0.84H), 7.37 (d, J = 7.1 Hz, 2H), 7.33−7.18 (m,
4014H), 7.14 (d, J = 8.3, 1H), 6.67 (d, J = 8.3 Hz, 1H), 6.24 (br s, 0.83H),
4026.18 (br s, 0.17H), 4.90 (d, J = 15.6 Hz, 1H), 4.77 (d, J = 15.7 Hz,
4031H), 4.01−3.84 (m, 1H), 3.75−3.56 (m, 1H), 2.34 (s, 0.5H), 2.29 (s,
4042.5H), 0.83−0.68 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 175.5,
405164.4, 151.9, 149.8, 141.1, 135.2, 134.0, 129.7, 128.8 (2C), 128.5,
406127.8, 127.7 (2C), 124.3, 110.3, 98.1, 63.4, 60.1, 44.4, 19.3, 13.6;
407HRMS (ESI) calcd for C22H20ClN3NaO4
+ [MNa]+ 448.1035, found
408448.1049; enantiomeric excess: 74%, determined by chiral HPLC (n-
409hexane:isopropanol = 70:30, ﬂow rate 1.0 mL/min): tR = 9.05 min
410(major), tR = 16.45 min (minor).
411(S)-Ethyl 1-Benzyl-6-chloro-6′-methyl-2,2′-dioxo-2′,3′-dihydro-
4121′H-spiro[indoline-3,4′-pyrimidine]-5′-carboxylate 5g. Prepared ac-
413cording to the general procedure starting from 6-chloro-N-benzyl
414isatin and ethyl acetoacetate; FC:dichloromethane:methanol, 97.5:2.5;
415yield: 62%; white solid; mp 213-214 °C; [α]D
20 − 1.0 (c 0.3, CHCl3);
416
1H NMR (300 MHz, CDCl3) δ 8.44 (br s, 1H), 7.39 (d, J = 7.0 Hz,
4172H), 7.35−7.22 (m, 3H), 7.19 (d, J = 7.7 Hz, 1H), 6.98 (d, J = 7.6 Hz,
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418 1H), 6.79 (s, 1H), 6.14 (br s, 1H), 4.90 (d, J = 15.5 Hz, 1H), 4.75 (d, J
419 = 15.5 Hz, 1H), 3.90 (m, 1H), 3.60 (m, 1H), 2.29 (s, 3H), 0.74 (t, J =
420 6.8 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 175.8, 164.4, 151.9, 149.4,
421 143.9, 135.6, 135.1, 130.7, 128.8 (2C), 127.9, 127.8 (2C), 124.8, 123.1,
422 109.9, 98.4, 63.0, 60.1, 44.4, 19.2, 13.6; HRMS (ESI) calcd for
423 C22H20ClN3NaO4
+ [MNa]+ 448.1035, found 448.1039; enantiomeric
424 excess: 77%, determined by chiral HPLC (n-hexane:isopropanol =
425 65:35, ﬂow rate 1.0 mL/min): tR = 8.65 min (major), tR = 15.35 min
426 (minor).
427 (S)-Ethyl 1-Benzyl-6-bromo-6′-methyl-2,2′-dioxo-2′,3′-dihydro-
428 1′H-spiro[indoline-3,4′-pyrimidine]-5′-carboxylate 5h. Prepared ac-
429 cording to the general procedure starting from 6-bromo-N-benzyl
430 isatin and ethyl acetoacetate; FC:dichloromethane:methanol, 97.5:2.5;
431 yield: 63%; white solid; mp 221−222 °C; [α]D20 + 7.6 (c 0.55, CHCl3);
432
1H NMR (300 MHz, CDCl3) δ 8.52 (br s, 1H), 7.39 (d, J = 7.3 Hz,
433 2H), 7.26 (m, 3H), 7.18−7.06 (m, 2H), 6.95 (s, 1H), 6.22 (br s, 1H),
434 4.87 (d, J = 15.6 Hz, 1H), 4.75 (d, J = 15.6 Hz, 1H), 4.00−3.77 (m,
435 1H), 3.70−3.49 (m, 1H), 2.27 (s, 3H), 0.72 (t, J = 7.1 Hz, 3H). 13C
436 NMR (75 MHz, CDCl3) δ 175.7, 164.4, 152.0, 149.5, 144.0, 135.1,
437 131.3, 128.8 (2C), 127.9, 127.8 (2C), 126.1, 125.2, 123.4, 112.6, 98.3,
438 63.1, 60.1, 44.1, 19.2, 13.6; HRMS (ESI) calcd for C22H20BrN3NaO4
+
439 [MNa]+ 492.0529, found 492.0518; enantiomeric excess: 75%,
440 determined by chiral HPLC (n-hexane:isopropanol = 70:30, ﬂow
441 rate 1.0 mL/min): tR = 9.35 min (major), tR = 16.50 min (minor).
442 (S)-Methyl 1-Benzyl-6′-methyl-2,2′-dioxo-2′,3′-dihydro-1′H-
443 spiro[indoline-3,4′-pyrimidine]-5′-carboxylate 5i. Prepared accord-
444 ing to the general procedure starting from N-benzyl isatin and methyl
445 acetoacetate; FC:dichloromethane:methanol, 97.5:2.5; yield: 65%;
446 white solid; mp 143−144 °C; [α]D20 − 6.8 (c 0.35, CHCl3); 1H
447 NMR (300 MHz, CDCl3) δ 7.77 (br s, 1H), 7.40 (d, J = 7.7 Hz, 2H),
448 7.36−7.23 (m, 4H), 7.20 (td, J = 7.8, 1.2 Hz, 1H), 7.01 (t, J = 7.5 Hz,
449 1H), 6.75 (d, J = 7.7 Hz, 1H), 5.29 (br s, 1H), 4.94 (d, J = 15.5 Hz,
450 1H), 4.83 (d, J = 15.4 Hz, 1H), 3.20 (s, 3H), 2.37 (s, 3H). 13C NMR
451 (75 MHz, CDCl3) δ 175.8, 165.0, 151.3, 149.2, 142.3, 135.6, 132.1,
452 129.9, 128.8 (2C), 127.9 (2C), 127.8, 123.8, 123.3, 109.2, 98.7, 63.5,
453 51.0, 44.3, 19.4; HRMS (ESI) calcd for C21H19N3NaO4
+ [MNa]+
454 400.1268, found 400.1257; enantiomeric excess: 61%, determined by
455 chiral HPLC (n-hexane:isopropanol = 70:30, ﬂow rate 1.0 mL/min):
456 tR = 9.15 min (major), tR = 18.30 min (minor).
457 (S)-Benzyl 1-Benzyl-6′-methyl-2,2′-dioxo-2′,3′-dihydro-1′H-spiro-
458 [indoline-3,4′-pyrimidine]-5′-carboxylate 5j. Prepared according to
459 the general procedure starting from N-benzyl isatin and benzyl
460 acetoacetate; FC:dichloromethane:methanol, 97.5:2.5; yield: 55%;
461 white solid; mp 147−148 °C; [α]D20 + 17.2 (c 0.5, dioxane); 1H
462 NMR (300 MHz, CDCl3) δ 8.15 (br s, 1H), 7.41−7.17 (m, 10H),
463 7.18−7.09 (m, 1H), 6.98 (t, J = 7.5 Hz, 1H), 6.85 (d, J = 6.5 Hz, 1H),
464 6.44 (d, J = 7.8 Hz, 1H), 5.39 (br s, 1H), 4.85−4.70 (m, 2H), 4.63 (d,
465 J = 12.0 Hz, 1H), 3.81 (d, J = 15.6 Hz, 1H), 2.39 (s, 3H). 13C NMR
466 (75 MHz, CDCl3) δ 175.8, 164.4, 162.2, 150.2, 142.3, 135.8, 132.2,
467 129.9, 128.9 (4C), 128.6 (2C), 128.3, 127.8, 127.7 (2C), 124.0, 123.4,
468 109.8, 66.5, 43.8, 19.6 (3 quaternary carbons are missed); HRMS
469 (ESI) calcd for C27H23N3NaO4
+ [MNa]+ 476.1581, found 476.1589;
470 enantiomeric excess: 74%, determined by chiral HPLC (n-
471 hexane:isopropanol = 80:20, ﬂow rate 1.0 mL/min): tR = 13.50 min
472 (major), tR = 28.20 min (minor).
473 Procedure for the Synthesis of Ethyl (S)-1,1′-Dibenzyl-6′-
474 methyl-2,2′-dioxo-2′,3′-dihydro-1′H-spiro[indoline-3,4′-pyri-
475 midine]-5′-carboxylate (6). To a solution of compound 5a (0.25
476 mmol, 1 equiv) in anhydrous dimethylformamide (0.830 mL, 0.3 M)
477 was added CsCO3 (0.33 mmol, 1.3 equiv); then, the mixture was
478 stirred for 1 h at room temperature. Benzyl bromide (0.38 mmol, 1.5
479 equiv) was slowly added, and the mixture was stirred overnight. After
480 the completion of reaction (monitored by TLC), saturated aq. NaCl
481 (1 mL) was added. The reaction mixture was extracted with ethyl
482 acetate (3 × 2 mL). The combined organic layer was washed with
483 water (2 × 6 mL), followed by brine (2 × 6 mL). The organic phase
484 was dried over anhydrous Na2SO4 and concentrated in vacuo to aﬀord
485 the crude product, which was puriﬁed by FC (n-hexane:ethyl acetate,
486 7:3), aﬀording the desired product 6 (115 mg, 96%) as a white solid;
487 mp 91−92 °C; [α]D20 − 32.4 (c 0.5, CHCl3); 1H NMR (300 MHz,
488CDCl3) δ 7.51−7.24 (m, 11H), 7.21 (d, J = 7.7 Hz, 1H), 7.02 (t, J =
4897.4 Hz, 1H), 6.75 (d, J = 7.8 Hz, 1H), 5.32 (d, J = 17.0 Hz, 1H), 5.16
490(br s, 1H), 5.00−4.78 (m, 3H), 3.91−3.73 (m, 1H), 3.57−3.42 (m,
4911H), 2.40 (s, 3H), 0.52 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz,
492CDCl3) δ 175.9, 165.1, 152.2, 150.7, 142.9, 137.7, 135.6, 131.7, 129.8,
493128.9 (2C), 128.7 (2C), 127.8 (3C), 127.1, 126.0 (2C), 123.9, 123.2,
494109.1, 101.9, 62.3, 60.0, 46.0, 44.2, 16.8, 13.2; HRMS (ESI) calcd for
495C29H27N3NaO4
+ [MNa]+ 504.1894, found 504.1898.
496Procedure for the Synthesis of (S)-1-Benzyl-6′-methyl-2,2′-
497dioxo-2′,3′-dihydro-1′H-spiro[indoline-3,4′-pyrimidine]-5′-car-
498boxylic Acid (7). Palladium (10 wt % on carbon, 0.025 mmol, 0.05
499equiv) was added to a solution of Biginelli-adduct 5j (0.50 mmol, 1
500equiv) and Et3N (0.50 mmol, 1 equiv) in 7.5 mL of dioxane/methanol
501(2:1). The reaction mixture was degassed in vacuo, placed under an
502atmosphere of H2 (g), and stirred in the dark at rt for 3h. The mixture
503was ﬁltered through a pad of Celite eluting with methanol (10 mL),
504and the combined organic layers were concentrated in vacuo to give
505the crude carboxylic acid derivative 7 (173 mg, 95%) as a white solid,
506suﬃciently pure to be directly used in the next step; mp not measured
507(decomposition); [α]D
20 − 19.2 (c 0.25, CHCl3); 1H NMR (300 MHz,
508DMSO-d6) δ 11.97 (br s, 1H), 9.39 (br s, 1H), 7.89 (br s, 1H), 7.47
509(d, J = 6.7 Hz, 2H), 7.39−7.25 (m, 3H), 7.23 (d, J = 7.2 Hz, 1H), 7.16
510(t, J = 7.7 Hz, 1H), 6.98 (t, J = 7.4 Hz, 1H), 6.62 (d, J = 7.7 Hz, 1H),
5114.96 (d, J = 16.3 Hz, 1H), 4.70 (d, J = 16.3 Hz, 1H), 2.29 (s, 3H); 13C
512NMR (75 MHz, DMSO-d6) δ 176.1, 166.4, 150.7, 149.4, 142.7, 136.3,
513133.9, 128.8, 128.3 (2C), 127.1 (2C), 127.0, 123.0, 122.3, 108.9, 97.8,
51463.0, 43.4, 18.5; HRMS (ESI) calcd for C20H17N3NaO4
+ [MNa]+
515386.1111, found 386.1121.
516Procedure for the Synthesis of (R)-1-Benzyl-6′-methyl-1′H-
517spiro[indoline-3,4′-pyrimidine]-2,2′(3′H)-dione (8). To a sol-
518ution of the carboxylic acid derivative 7 (0.1 mmol, 1 equiv) in 1 mL
519of dioxane/methanol (1:1) was added hydrochloric acid in dioxane (4
520M, 0.4 mmol, 4 equiv), and the reaction was stirred at 90 °C for 0.5 h.
521The solvent was removed under reduced pressure to aﬀord compound
5228 (31 mg, 98%) in high purity as a white solid, with no need for further
523puriﬁcations; mp 95−96 °C; [α]D20 − 25.6 (c 0.5, CHCl3); 1H NMR
524(400 MHz, CDCl3) δ 7.82 (br s, 1H), 7.40 (d, J = 7.3 Hz, 1H), 7.37−
5257.23 (m, 5H), 7.18 (t, J = 7.7 Hz, 1H), 7.06 (t, J = 7.5 Hz, 1H), 6.71
526(d, J = 7.8 Hz, 1H), 5.72 (br s, 1H), 4.93 (d, J = 15.6 Hz, 1H), 4.79 (d,
527J = 15.6 Hz, 1H), 4.24 (s, 1H), 1.86 (s, 3H). 13C NMR (100 MHz,
528CDCl3) δ 177.2, 154.4, 142.0, 136.4, 136.1, 132.6, 130.5, 129.5 (2C),
529128.4, 128.0 (2C), 125.7, 124.2, 110.2, 95.4, 64.3, 44.7, 19.4; HRMS
530(ESI) calcd for C19H17N3NaO2
+ [MNa]+ 342.1213, found 342.1206.
531Procedure for the Synthesis of Diastereoisomers (S)-1-
532Benzyl-6′-methyl-2,2′-dioxo-N-((S)-1-phenylethyl)-2′,3′-dihy-
533dro-1′H-spiro[indoline-3,4′-pyrimidine]-5′-carboxamide (9a)
534and (R)-1-Benzyl-6′-methyl-2,2′-dioxo-N-((S)-1-phenylethyl)-
5352′,3′-dihydro-1′H-spiro[indoline-3,4′-pyrimidine]-5′-carboxa-
536mide (9b). To a solution of carboxylic acid derivative 8 (0.9 mmol, 1
537equiv) and DIPEA (1.8 mmol, 2 equiv) in 9.4 mL of anhydrous
538dimethylformamide was added HATU (1.4 mmol, 1.5 equiv). After 5
539min, (S)-(−)-α-methylbenzylamine (0.9 mmol, 1 equiv) and DIPEA
540(1.8 mmol, 2 equiv) were added, and the reaction was stirred at room
541temperature for 24 h. The resulting mixture was partitioned between
542ethyl acetate (20 mL) and water (20 mL). The organic phase was
543washed with brine (6 × 10 mL), dried over Na2SO4, and concentrated
544in vacuo to aﬀord the crude diastereoisomeric mixture 9, which was
545puriﬁed by ﬂash chromatography (ethyl acetate:n-hexane, 95:5),
546obtaining the two isolated stereoisomers 9a (358 mg, 86%) and 9b
547(54 mg, 12%).
5489a. White solid; mp 149−150 °C; [α]D20 + 16.5 (c 0.9, CHCl3); 1H
549NMR (400 MHz, DMSO-d6) δ 8.79 (br s, 1H), 8.18 (d, J = 8.4 Hz,
5501H), 7.62 (br s, 1H), 7.46 (d, J = 7.3 Hz, 2H), 7.33 (d, J = 7.4 Hz,
5511H), 7.32−7.22 (m, 7H), 7.18 (q, J = 8.4, 7.8 Hz, 2H), 7.00 (t, J = 7.5
552Hz, 1H), 6.63 (d, J = 7.8 Hz, 1H), 4.78 (s, 2H), 4.71−4.59 (m, 1H),
5531.91 (s, 3H), 1.04 (d, J = 7.0 Hz, 3H). 13C NMR (100 MHz, DMSO-
554d6) δ 177.4, 165.6, 153.2, 145.3, 144.4, 138.0, 137.3, 132.4, 130.2,
555129.4 (2C), 129.3 (2C), 128.3 (2C), 128.1, 127.6, 127.2 (2C), 125.3,
556123.0, 109.9, 105.1, 64.3, 48.6, 44.2, 23.0, 18.3. HRMS (ESI) calcd for
557C28H26N4NaO3
+ [MNa]+ 489.1897, found 489.1905.
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558 9b. White solid; mp 138−139 °C; [α]D20 − 89.5 (c 1, CHCl3); 1H
559 NMR (400 MHz, DMSO-d6) δ 8.81 (br s, 1H), 8.13 (d, J = 8.3 Hz,
560 1H), 7.62 (br s, 1H), 7.42 (d, J = 6.4 Hz, 2H), 7.31 (d, J = 7.2 Hz,
561 1H), 7.29−7.19 (m, 3H), 7.17 (t, J = 7.6 Hz, 1H), 7.11 (m, 3H), 7.00
562 (t, J = 7.4 Hz, 1H), 6.83 (d, J = 7.4 Hz, 2H), 6.57 (d, J = 7.8 Hz, 1H),
563 4.88−4.67 (m, 3H), 2.01 (s, 3H), 1.32 (d, J = 7.0 Hz, 3H). 13C NMR
564 (100 MHz, DMSO-d6) δ 177.4, 165.6, 153.0, 144.9, 144.32, 138.3,
565 137.3, 132.7, 130.1, 129.4 (2C), 128.9 (2C), 128.2 (2C), 128.07,
566 127.1, 126.8 (2C), 125.3, 123.2, 110.0, 105.12, 64.4, 48.1, 44.2, 22.5,
567 18.4. HRMS (ESI) calcd for C28H26N4NaO3
+ [MNa]+ 489.1897,
568 found 489.1909.
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